Astec Lifesciences Limited reported a consolidated net loss of ₹187 million for the quarter ended June 30, 2026 (Q1FY27), a significant improvement from the ₹330 million loss recorded in the same period last year. This reduction in losses occurred even as consolidated revenue from operations declined to ₹836 million, down from ₹911 million in Q1FY26. The results, which reflect improved cost management amidst top-line pressure, were approved by the Board of Directors on July 31, 2026, following recommendations from the Audit Committee.

The financial disclosure was made pursuant to Regulation 30 read with Schedule III and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The unaudited financial results were published in newspaper advertisements on August 1, 2026, in Business Standard (English) and Mumbai Lakshdeep (Marathi). Tejashree Rohan Pradhan, Company Secretary & Compliance Officer, signed the exchange filing confirming the publication.

Q1FY27 Financial Performance

The company’s bottom-line improvement highlights operational efficiencies despite a contraction in sales. The year-on-year comparison reveals a narrowing loss burden, suggesting that cost-cutting measures or reduced expenditure outpaced the decline in revenue generation.

Key Takeaways

• Net loss narrowed by approximately 43% year-on-year, dropping from ₹330 million to ₹187 million.
• Revenue declined to ₹836 million from ₹911 million in the corresponding quarter of the previous fiscal year.
• The divergence between falling revenue and shrinking losses indicates improved margin dynamics or lower operating expenses during the quarter.

What the Numbers Show

The primary driver behind the improved net loss figure is not revenue growth but rather a reduction in the loss magnitude relative to the prior year. With revenue contracting by roughly 8% (from ₹911 million to ₹836 million), the ability to cut the net loss by over ₹140 million suggests significant structural changes in the company’s cost base or one-time adjustments that benefited the bottom line. Investors should monitor whether this cost discipline can be sustained as the company navigates continued top-line challenges in FY27.

Astec LifeSciences Limited has scheduled its 32nd Annual General Meeting (AGM) for Friday, July 31, 2026, at 4:00 p.m. IST via Video Conferencing (VC) and Other Audio Visual Means (OAVM). The meeting will be held to transact business including the adoption of audited financial statements for the Financial Year 2025-26 and the ratification of the Cost Auditor's remuneration. The company has confirmed the completion of dispatch of the AGM notice and Annual Report to shareholders, with advertisements published in Business Standard and Mumbai Lakshadeep on July 9, 2026.

AGM Schedule and Key Dates

Shareholders should note the following key dates associated with the 32nd AGM:

The venue of the 32nd AGM shall be deemed to be the Registered Office of the Company at "Godrej One", 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai – 400 079, Maharashtra, India. E-voting facilities are being provided through the National Securities Depository Limited (NSDL) platform.

Agenda Items at the 32nd AGM

The following business items are proposed to be transacted at the 32nd AGM:

• Ordinary Business: Adoption of Audited Financial Statements (Standalone and Consolidated) for the Financial Year ended March 31, 2026, along with the Reports of the Board of Directors and Statutory Auditors.
• Ordinary Business: Re-appointment of Mr. Ashok V. Hiremath (DIN: 00349345), Non-Executive, Non-Independent Director, who retires by rotation and is eligible for re-appointment.
• Special Business: Ratification of remuneration of M/s. Tapan Gaitonde & Co., Cost Accountants, as Cost Auditor of the Company for the Financial Year ending March 31, 2027, at a remuneration of up to ₹1,50,000/- (Rupees One Lakh Fifty Thousand Only) per annum plus ₹15,000/- (Rupees Fifteen Thousand Only) towards XBRL compilation, plus applicable GST and reimbursement of out-of-pocket expenses.

IEPF and Unclaimed Dividend Notice

Shareholders are informed that the dividend amount for FY 2018-19 remaining unclaimed shall become due for transfer to the Investor Education and Protection Fund (IEPF) on Wednesday, August 26, 2026. Shareholders are requested to submit their claims preferably by Friday, August 7, 2026 to avoid transfer to IEPF. During FY 2025-26, 1,371 Equity Shares of Face Value of ₹10/- each, amounting to a nominal value of ₹13,710/-, were transferred to IEPF on account of unclaimed dividend for FY 2017-18.